To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials
AJOB Empirical Bioethics 9 (2):82-90 (2018)
Abstract
This article has no associated abstract. (fix it)My notes
Similar books and articles
Serial Participation and the Ethics of Phase 1 Healthy Volunteer Research.Rebecca L. Walker, Marci D. Cottingham & Jill A. Fisher - 2018 - Journal of Medicine and Philosophy 43 (1):83-114.
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
Selected Issues Related to the Conduct, Reporting, and Analysis of Phase I Trials.Marcelle Denise Winget - 1996 - Dissertation, The Johns Hopkins University
Cost‐effectiveness of an electronic medication ordering and administration system in reducing adverse drug events.Robert C. Wu, Audrey Laporte & Wendy J. Ungar - 2007 - Journal of Evaluation in Clinical Practice 13 (3):440-448.
An evolutionary approach to realism-based adverse event representations.Werner Ceusters, Maria Capolupo, G. De Moor, J. Devlies & Barry Smith - 2011 - Methods of Information in Medicine 50 (1):62-73.
The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials.Spencer Phillips Hey & Jonathan Kimmelman - 2014 - Kennedy Institute of Ethics Journal 24 (2):121-139.
Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results.John D. Banja & Boadie Dunlop - 2009 - American Journal of Bioethics 9 (8):39-41.
Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.N. Sofaer, C. Thiessen, S. D. Goold, J. Ballou, K. A. Getz, G. Koski, R. A. Krueger & J. S. Weissman - 2009 - Journal of Medical Ethics 35 (3):183-188.
Payments to Normal Healthy Volunteers in Phase 1 Trials: Avoiding Undue Influence While Distributing Fairly the Burdens of Research Participation.A. S. Iltis - 2009 - Journal of Medicine and Philosophy 34 (1):68-90.
An evolutionary approach to the representation of adverse events.Werner Ceusters, Maria Capolupo, Barry Smith & Georges De Moor - 2009 - Studies in Health Technology and Informatics 150:537-541.
Assessing the detection, reporting and investigation of adverse events in clinical trial protocols implemented in Cameroon: a documentary review of clinical trial protocols.Akoh Walter Ebile, Jerome Ateudjieu, Martin Ndinakie Yakum, Marceline Ngounoue Djuidje & Pierre Watcho - 2015 - BMC Medical Ethics 16 (1):1-9.
Deception in the Single-Blind Run-In Phase of Clinical Trials.Howard Mann - 2007 - IRB: Ethics & Human Research 29 (2).
Phase I cancer trials: A collusion of misunderstanding.Matthew Miller - 2000 - Hastings Center Report 30 (4):34-43.
Strategies to Minimize Risks and Exploitation in Phase One Trials on Healthy Subjects.Adil E. Shamoo & David B. Resnik - 2006 - American Journal of Bioethics 6 (3):W1-W13.
Analytics
Added to PP
2018-04-27
Downloads
19 (#588,866)
6 months
2 (#297,033)
2018-04-27
Downloads
19 (#588,866)
6 months
2 (#297,033)
Historical graph of downloads
Citations of this work
Promoting Ethical Payment in Human Infection Challenge Studies.Holly Fernandez Lynch, Thomas C. Darton, Jae Levy, Frank McCormick, Ubaka Ogbogu, Ruth O. Payne, Alvin E. Roth, Akilah Jefferson Shah, Thomas Smiley & Emily A. Largent - 2021 - American Journal of Bioethics 21 (3):11-31.
A Proposal for Fair Compensation for Research Participants.Emily E. Anderson - 2019 - American Journal of Bioethics 19 (9):62-64.
The ethical anatomy of payment for research participants.Joanna Różyńska - 2022 - Medicine, Health Care and Philosophy 25 (3):449-464.
Appraising Harm in Phase I Trials: Healthy Volunteers' Accounts of Adverse Events.Lisa McManus, Arlene Davis, Rebecca L. Forcier & Jill A. Fisher - 2019 - Journal of Law, Medicine and Ethics 47 (2):323-333.
Coercive Offers Without Coercion as Subjection.William R. Smith & Benjamin Rossi - 2019 - American Journal of Bioethics 19 (9):64-66.
References found in this work
Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials.Jill A. Fisher - 2015 - Science, Technology, and Human Values 40 (2):199-226.
Subversive Subjects: Rule‐Breaking and Deception in Clinical Trials.Rebecca Dresser - 2013 - Journal of Law, Medicine and Ethics 41 (4):829-840.
Subversive Subjects: Rule-Breaking and Deception in Clinical Trials.Rebecca Dresser - 2013 - Journal of Law, Medicine and Ethics 41 (4):829-840.
Payments to Normal Healthy Volunteers in Phase 1 Trials: Avoiding Undue Influence While Distributing Fairly the Burdens of Research Participation.A. S. Iltis - 2009 - Journal of Medicine and Philosophy 34 (1):68-90.
